U.S. General Anesthesia Drugs Market Estimated Worth 2 Billion USD by 2020

This market is expected to reach $207.3 Billion by 2020 from $114.7 Billion in 2015, growing at a CAGR of 12.6% from 2015 to 2020.


Seattle, WA -- (SBWIRE) -- 07/03/2017 -- This report "U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020", provides a detailed overview of the market for ketamine in the U.S., current market trends, supply chain, competitive analysis, market entry strategies, and revenue forecast. This market is expected to reach $207.3 Billion by 2020 from $114.7 Billion in 2015, growing at a CAGR of 12.6% from 2015 to 2020.

Browse 42 market data tables and 28 figures spread through 114 pages and in-depth TOC on "U.S. General Anesthesia Drugs Market"
Early buyers will receive 10% customization on reports.

Factors such as rapid rise in aging population, rising prevalence of cardiovascular and respiratory system-related diseases, and rising number of emergency surgeries are driving the growth of the U.S. General Anesthesia Drugs Market. However, side effects associated with ketamine usage (such as elevation in blood pressure and heart rate, amnesia, respiratory depression, and hallucinations), regulatory issues, and lower compliance rates in comparison with other anesthetic drugs are likely to restrain the growth of this market.

Get The PDF Brochure For This Report@

The market is segmented on the basis of molecule and route of administration. On the basis of molecules, the market is divided into Propofol, Benzodiazepine, Ketamine (S-(+)-Ketamine HCL), and Methohexital Sodium. Propofol is expected to be fastest-growing segment, owing to its greater preference and rapid onset of action.

Ask for Discount on this Report@

On the basis of route of administration, the U.S. General Anesthesia Drugs Market is bifurcated into intravenous and inhalational. The intravenous segment is expected to account for the largest share of the U.S. General Anesthesia Drugs Market in 2015. Greater patient compliance and less number of side effects as compared to inhalational anesthetics are driving the growth of this market.

Major players operating in the U.S. General Anesthesia Drugs Market are AstraZeneca plc (U.K.), Baxter International Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Mylan N.V. (U.S.), Eisai Co., Ltd. (Japan), Fresenius Se & Co. KGaA (Germany), Hospira, Inc. (U.S.), and Par Pharmaceutical Companies, Inc. (U.S.).

About MarketsandMarkets™:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their pain points around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 Micro Quadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Mr. Rohan
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: 1-888-600-6441